Literature DB >> 32958159

Worth looking! venous thromboembolism in patients who undergo preperitoneal pelvic packing warrants screening duplex.

Alicia A Heelan1, Mari Freedberg2, Ernest E Moore3, Barry K Platnick4, Fredric M Pieracci5, Mitchell J Cohen6, Ryan Lawless7, Eric M Campion8, Jamie J Coleman9, Melanie Hoehn10, Clay Cothren Burlew11.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) in patients with major pelvic fractures who undergo preperitoneal pelvic packing (PPP) has not been investigated. We hypothesized that patients who undergo PPP are at high risk for VTE, thus early prophylactic anticoagulation and screening duplex are warranted. STUDY
DESIGN: All patients requiring PPP from 2015 to 2019 were reviewed. Management and outcomes were analyzed.
RESULTS: During the study period, 79 patients underwent PPP. Excluding the early deaths, 17 patients had deep venous thrombosis (DVT) and 6 had pulmonary emboli (PE); 4 patients had both DVT/PE. Overall mortality was 15%. Thirty-two patients underwent screening duplex within 72 h of admission and 10 were positive for DVT.
CONCLUSION: Patients with complex pelvic trauma undergoing PPP have a 23% incidence of DVT and an additional 8% incidence of PE. 31% of screening ultrasounds are positive. The overall mortality was 15%. With a high incidence of VTE in this patient population, we recommend screening duplex ultrasounds.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Pelvic fracture; Pelvic trauma; Preperitoneal pelvic packing; Venous thromboembolism

Mesh:

Year:  2020        PMID: 32958159     DOI: 10.1016/j.amjsurg.2020.08.043

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  The Perioperative Deep Vein Thrombosis in Lower Extremities in Patients With Pelvic Fracture: A Case-Control Study.

Authors:  Yun Yan; Baobao Zhang; Jie Yang; Yan Zhang; Lei Zhang; Dan Wang; Jing Gao; Lianzhi He; Pengfei Wang; Yan Zhuang; Kun Zhang; Ping Liu
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.